Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis

Gut

Volumn 48, Issue 6, 2001, Pages 843-848

  Gramenzi, A ^a   Andreone, P ^a,f   Fiorino, S ^a   Camma C ^b   Giunta, M ^c   Magalotti, D ^a   Cursaro, C ^a   Calabrese, C ^a   Arienti, V ^a,d   Rossi, C ^a   Di Febo, G ^a   Zoli, M ^a   Craxi, A ^c   Gasbarrini, G ^a,e   Bernardi, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma; Interferon alfa

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ALPHA INTERFERON; AMINOTRANSFERASE; BILIRUBIN; PROTHROMBIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; BLEEDING; BRAIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE;

ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035000041     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.6.843     Document Type: Article

References (31)

1. 1 Chiaramonte M, Stroffolini T, Caporaso N, et al. Hepatitis C virus infection in Italy: a multicentric seroepidemiological study (a report from the HCV study group of the Italian Association for the Study of the Liver). Ital J Gastroenterol 1991;23:555-8.
2. 2 De Bac C, Stroffolini T, Gaeta GB, et al. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 1994;20:1442-9.
3. 3 Seef LB, Natural history of hepatitis C. Hepatology 1997;26(suppl I):21-8S.
4. 4 Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
5. 5 Andreone P, Cursaro C, Gramenzi A, et al. Interferon and hepatocellular carcinoma, Lancet 1996;347:195.
6. 6 Mazzella G, Accogli E, Sottili S, et al. Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7.
7. 7 Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in European patients with cirrhosis type C. J Hepatol 1997;27:201-5.
8. 8 Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
9. 9 International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351;1535-9.
10. 10 Serfaty L, Aumaître H, Cazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
11. 11 Benvegnu̇ L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83: 901-9.
12. 12 Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94-9.
13. 13 Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
14. 14 Valla D-C, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized controlled trial of interferon alfa 2b versus no treatment. Hepatology 1999;29:1870-5.
15. 15 Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81.
16. 16 Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112: 463-72.
17. 17 Cammà C; Di Marco V, Lo Iacono O, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998;28:531-7.
18. 18 Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology 1998;27:1443-4.
19. 19 Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977-85.
20. 20 Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981;27:213-18.
21. 21 Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation. II. Analysis and examples. Br J Cancer 1977;35:1-39
22. 22 Cox DR. Regression models and life tables (with discussion). J R Statist Soc B 1972;34:187-220.
23. 23 SAS Technical Report, SAS/STAT Software: changes and enhancements, release 6.07. Cary, NC: SAS Institute Inc, 1992.
24. 24 Koretz RL. Interferon and hepatocellular carcinoma, Lancet 1996;347:194-5.
25. 25 Baffis V, Shrier I, Sherker A, et al. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999;131:696-701.
26. 26 Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Philadelphia: Lippincott, Williams and Wilkins, 1991.
27. 27 National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997;26(suppl I):2-10S.
28. 28 EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999;31(suppl I):3-8.
29. 29 Idilman R, De Maria N, Colantoni A, et al. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepat 1997;4:81-91.
30. 30 Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:I797-801.
31. 31 Oka H, Tamori A, Kuroki T, et al. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-6.